Safety of Intratracheal Administration of Human Umbilical Cord Blood Derived Mesenchymal Stromal Cells in Extremely Low Birth Weight Preterm Infants
- PMID: 30992220
- DOI: 10.1016/j.jpeds.2019.02.029
Safety of Intratracheal Administration of Human Umbilical Cord Blood Derived Mesenchymal Stromal Cells in Extremely Low Birth Weight Preterm Infants
Abstract
In a phase 1 dose-escalation trial at 2 dosing levels, we assessed the safety of intratracheal administration of a single-dose of human umbilical cord blood-derived mesenchymal stromal cells in 12 extremely low birth weight infants <28 weeks of gestation and <1000 g at birth at 5-14 days of life. The treatment was well tolerated and appears to be safe and feasible, and warrants a larger randomized-controlled blinded study. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02381366.
Keywords: BPD; MSCs; NICU; chronic lung disease; neonatal; neonatal intensive care unit; newborn; prematurity; stem cells.
Copyright © 2019. Published by Elsevier Inc.
Comment in
-
Stem cells for bronchopulmonary dysplasia: A promising yet challenging journey lies ahead.J Pediatr. 2019 Sep;212:246. doi: 10.1016/j.jpeds.2019.05.063. Epub 2019 Jun 27. J Pediatr. 2019. PMID: 31255387 No abstract available.
-
Reply.J Pediatr. 2019 Sep;212:246-247. doi: 10.1016/j.jpeds.2019.05.064. Epub 2019 Jul 9. J Pediatr. 2019. PMID: 31300311 No abstract available.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
